DENNIS CARSON, MD
Osteopathic Medicine at Torrey Pines Rd, La Jolla, CA
License number
California G21459
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
2880 Torrey Pines Rd, La Jolla, CA 92093
Phone
(858) 534-5408
Organization information
See more information about DENNIS CARSON at bizstanding.comDennis A Carson MD
9500 Gilman Dr, La Jolla, CA 92093
Categories:
Internal Medicine Physicians & Surgeons, Rheumatology Physicians & Surgeons
Phone:
(858) 534-1501 (Phone)
Professional information
Dr. Dennis A Carson, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Rheumatology
Address:
9500 Gilman Dr, La Jolla 92093
Certifications:
Internal Medicine, 1973, Rheumatology, 1976
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1970
U C S D Medical Center-Hillcrest
University Of California, San Diego
Columbia University / College of Physicians And Surgeons
Graduated: 1970
U C S D Medical Center-Hillcrest
University Of California, San Diego
Dennis Carson, La Jolla CA
Specialties:
Rheumatologist
Address:
2880 Torrey Pines Rd, La Jolla, CA 92037
Compounds Having Activity As Inhibitors Of Apoptosis
US Patent:
7601846, Oct 13, 2009
Filed:
Nov 10, 2005
Appl. No.:
11/271511
Inventors:
Howard B. Cottam - Escondido CA, US
Dennis A. Carson - La Jolla CA, US
Sylvie Barchechath - Geneva, CH
Dennis A. Carson - La Jolla CA, US
Sylvie Barchechath - Geneva, CH
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07D 513/04, A61K 31/429
US Classification:
548151, 544133, 546199, 5142332, 514322, 514366
Abstract:
The present invention provides compounds that can protect mammalian cells from the damaging effects of chemotherapy, irradiation, or in other situations in which it is desirable to protect tissue from the consequences of clinical or environmental stress.
Mutations In Wnt-Frizzled Signaling Pathways Associated With Osteoarthritis
US Patent:
2005013, Jun 16, 2005
Filed:
Sep 22, 2004
Appl. No.:
10/947849
Inventors:
Dennis Carson - La Jolla CA, US
Mary Corr - San Diego CA, US
John Loughlin - Headington, GB
Mary Corr - San Diego CA, US
John Loughlin - Headington, GB
Assignee:
REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C12Q001/68, G01N033/53, G01N033/567, C07H021/04
US Classification:
435006000, 514044000, 435007200, 536024300
Abstract:
This invention provides methods to identify individuals predisposed to developing osteoarthritis, to diagnose osteoarthritis, and to monitor the progression of the disease. The method also provides methods to identify modulators of bone development that affect a wnt/fzd signaling pathway and methods to prevent or treat osteoarthritis by administering the modulator of bone development.
Methods For High Sensitivity Detection Of Genetic Polymorphisms
US Patent:
2010008, Apr 8, 2010
Filed:
Jul 31, 2007
Appl. No.:
12/375912
Inventors:
Dennis A. Carson - La Jolla CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C12Q 1/68, C07H 21/04
US Classification:
435 6, 536 231
Abstract:
Multiplex PCR-based methods for detecting a variant polynucleotide having a nucleotide sequence differing from the wild-type nucleotide sequence of a nucleic acid molecule, wherein the variant polynucleotide is in a sample containing an excess of the wild-type nucleic acid molecule. The methods are particularly useful for detection of deletions from, or translocations and inversions in, genomic DNA. The susceptibility to, diagnosis of, and progression of a disease clinically related to the occurrence of such polymorphisms in an individual may also be confirmed and monitored using the multiplex PCR-based methods or by detecting RNA fusion transcripts in a sample that correspond to previously identified deletions, translocations or inversions in genomic DNA.
Methods For Identifying Compounds That Modulate Wnt Signaling In Cancer Cells
US Patent:
2010006, Mar 18, 2010
Filed:
May 7, 2009
Appl. No.:
12/437318
Inventors:
John Hood - San Diego CA, US
Charlene F. Barroga - San Diego CA, US
Dennis Carson - La Jolla CA, US
Desheng Lu - San Diego CA, US
Charlene F. Barroga - San Diego CA, US
Dennis Carson - La Jolla CA, US
Desheng Lu - San Diego CA, US
Assignee:
Wintherix LLC - San Diego CA
International Classification:
C12Q 1/68, C07D 473/32
US Classification:
435 6, 544276
Abstract:
Provided herein are methods for screening compounds for their ability to modulate Wnt signaling in cancer cells.
Combined Use Of Impdh Inhibitors With Toll-Like Receptor Agonists
US Patent:
2005000, Jan 6, 2005
Filed:
Apr 14, 2004
Appl. No.:
10/824833
Inventors:
Dennis Carson - La Jolla CA, US
Howard Cottam - Escondido CA, US
Jongdae Lee - San Diego CA, US
Howard Cottam - Escondido CA, US
Jongdae Lee - San Diego CA, US
Assignee:
REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K031/519, C07D498/02, C07D487/02
US Classification:
514260100, 514264110, 514265100, 544255000, 544279000, 544280000
Abstract:
The present invention provides a broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal and treating diseases such as cancer and autoimmune disease. These agents include TLR-ligands and ligand analogs which induce interferon production, in combination with inhibitors of inosine monophosphate dehydrogenase (IMPDH), that further enhance the induction of interferon production.
Uses Of Phospholipid Conjugates Of Synthetic Tlr7 Agonists
US Patent:
2013020, Aug 8, 2013
Filed:
Apr 29, 2011
Appl. No.:
13/695385
Inventors:
Dennis A. Carson - La Jolla CA, US
Howard B. Cottam - Escondido CA, US
Tomoko Hayashi - San Diego CA, US
Michael Chan - San Diego CA, US
Christina C.N. Wu - Escondido CA, US
Howard B. Cottam - Escondido CA, US
Tomoko Hayashi - San Diego CA, US
Michael Chan - San Diego CA, US
Christina C.N. Wu - Escondido CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 39/39, C07F 9/6561
US Classification:
4241841
Abstract:
The invention provides uses for phospholipid conjugates of TLR agonists, for instance in vaccines, and to prevent, inhibit or treat a variety of disorders including inflammation, cancer and pathogen, e.g., microbe, infection.
Amide Derivatives Of Ethacrynic Acid
US Patent:
2011030, Dec 15, 2011
Filed:
Dec 16, 2009
Appl. No.:
13/140613
Inventors:
Dennis A. Carson - La Jolla CA, US
Howard B. Cottam - Escondido CA, US
Guangyi Jin - Berkeley CA, US
Desheng Lu - San Diego CA, US
Howard B. Cottam - Escondido CA, US
Guangyi Jin - Berkeley CA, US
Desheng Lu - San Diego CA, US
Assignee:
The Regents of the The University of California - Oakland CA
International Classification:
A61K 31/165, A61P 35/00, A61P 35/02, C07C 233/01
US Classification:
514621, 564169
Abstract:
The invention provides ethacrynic acid derivatives useful to prevent, inhibit or treat a variety of disorders or diseases including cancer and inflammatory disorders.
Tlr Agonists
US Patent:
2009032, Dec 31, 2009
Filed:
Aug 21, 2006
Appl. No.:
12/064529
Inventors:
Dennis A. Carson - La Jolla CA, US
Kenji Takabayshi - Poway CA, US
Suzanne Grimshaw - Poway CA, US
Howard B. Cottam - Escondido CA, US
Michael Chan - San Diego CA, US
Christina C.N. Wu - Escondido CA, US
Kenji Takabayshi - Poway CA, US
Suzanne Grimshaw - Poway CA, US
Howard B. Cottam - Escondido CA, US
Michael Chan - San Diego CA, US
Christina C.N. Wu - Escondido CA, US
Assignee:
The Regents of The University of California Office of Technology Transfer - Oakland CA
International Classification:
A61K 45/00, C07D 473/00, A61K 31/522, C12N 1/20, C12N 7/00, A61P 35/00
US Classification:
424 934, 544276, 51426337, 4352525, 4352521, 4352528, 4352351, 424 935, 424 936
Abstract:
The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.